Enhanced antiviral benefit of combination therapy with lamivudine and famciclovir against WHV replication in chronic WHV carrier woodchucks

Antiviral Research

Volumn 45, Issue 1, 2000, Pages 19-32

  Korba, Brent E ^a   Cote, Paul ^a   Hornbuckle, William ^b   Schinazi, Raymond ^c   Gerin, John L ^a   Tennant, Bud C ^b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Combination antiviral therapy; Experimental animal model; Famciclovir; Hepatitis B Virus; Lamivudine; Woodchuck Hepatitis Virus

Indexed keywords

FAMCICLOVIR; LAMIVUDINE; PLACEBO; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; HEPATITIS B; HEPATITIS VIRUS; INFECTION; NONHUMAN; PRIORITY JOURNAL; VIRUS HEPATITIS; VIRUS REPLICATION; WOODCHUCK;

2-AMINOPURINE; ANIMALS; ANTIVIRAL AGENTS; CARRIER STATE; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HEPATITIS B VIRUS, WOODCHUCK; HEPATITIS B, CHRONIC; LAMIVUDINE; MARMOTA; PRODRUGS; REVERSE TRANSCRIPTASE INHIBITORS; VIREMIA; VIRUS REPLICATION;

ANAS SP.; ANIMALIA; DUCK HEPATITIS B VIRUS; FELINE CALICIVIRUS; HEPATITIS B VIRUS; MARMOTA MONAX; WOODCHUCK HEPATITIS B VIRUS;

EID: 0033955317     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(99)00072-8     Document Type: Article

References (38)

1. Bartholomeusz A., Groenen L.C., Locarnini S.A. Clinical experience with famciclovir against hepatitis B virus. Intervirology. 40:1997;337-342.
2. Beasley R.P., Hwang L.-Y. Overview on the epidemiology of hepatocellular carcinoma. Hollinger F.B., Lemon S.M., Margolis H. Viral Hepatitis and Liver Disease. 1991;532-534 Williams and Wilkins, Baltimore.
3. Bliss C. The toxicity of poisons applied jointly. Ann. Appl. Biol. 26:1939;585-615.
4. Block T.M., Lu X., Mehta A.S., Blumberg B.S., Tennant B., Ebling M., Korba B., Lansky D.M., Jacob G.S., Dwek R.A. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat. Med. 4:1998;610-614.
5. Colledge D., Locarnini S., Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology. 26:1997;216-225.
6. Cote P.J., Engle R.E., Langer C.A., Ponzetto A., Gerin J.L. Antigenic analysis of woodchuck hepatitis virus surface antigen with site-specific radioimmunoassays. J. Virol. 49:1984;701-708.
7. Cote P.J., Roneker C., Cass K., Schodel F., Peterson D., Tennant B., DeNoronha F., Gerin J.L. New enzyme immunoassays for the serologic detection of woodchuck hepatitis virus infection. Viral Immunol. 6:1993;161-169.
8. Cullen J.M., Smith S.L., Davis M.G., Dunn S.E., Botteron C., Cecchi A., Linsey D., Linzey D., Frick L., Paff M.T., Goulding A., Biron K. In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks. Antimicrob. Agents Chemother. 41:1997;2076-2082.
9. Fourel I., Hantz O., Watanabe K.A., Jacquet C., Chomel B., Fox J.J., Trepo C. Inhibitory effects of 2′-fluorinated arabinosyl-pyrimidine nucleosides to woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob. Agents Chemother. 34:1990;473-475.
10. Ganem D. Hepadnaviridae: The viruses and their replication. Fields B.N., Howley P. Fields Virology. 1997;2703-2737 Lippincott-Raven, Philadelphia, PA.
11. Gangemi J.D., Korba B.E., Tennant B.C., Udea H., Jay G. Antiviral and anti-proliferative activities of a-interferons in experimental hepatitis B virus infections. Antiviral Ther. 1:1997;64-70.
12. Genovesi E.V., Lamb L., Medina I., Taylor D., Seifer M., Innaimo S., Colonno R.J., Standring D.N., Clark J.M. Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob. Agents Chemother. 42:1998;3209-3217. (Published erratum appears in Antimicrob. Agents Chemother. 1999 43(3), 726).
13. Gerin J.L., Cote P.J., Korba B.E., Miller R.H., Purcell R.H., Tennant B.C. Hepatitis B virus and liver cancer: the woodchuck as an experimental model of hepadnavirus-induced liver cancer. Hollinger F.B., Lemon S.M., Margolis H.S. Viral Hepatitis and Liver Disease. 1991;556-559 Williams and Wilkins, Baltimore.
14. Hurwitz S., Tennant B., Korba B., Gerin J., Schinazi R. Viral pharmacodynamics of (-)β-2′,3′-dideoxy-3′-thiacytidine in chronically infected woodchucks compared to humans. Antimicrob. Agents Chemother. 42:1998;2804-2809.
15. Jaeckel E., Manns M.P. Experience with lamivudine against hepatitis B virus. Intervirology. 40:1997;322-336.
16. Korba B.E. In vitro evaluation of combination therapies against hepatitis B virus replication. Antiviral Res. 29:1996;49-51.
17. Korba B.E., Boyd M.R. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob. Agents Chemother. 40:1996;1282-1284.
18. Korba B.E., Wells F., Tennant B.C., Yoakum G.H., Purcell R.H., Gerin J.L. Hepadnavirus infection of peripheral blood lymphocytes in vivo: woodchuck and chimpanzee models of viral hepatitis. J. Virol. 58:1986;1-8.
19. Korba B.E., Cote P.J., Tennant B.C., Gerin J.L. Woodchuck hepatitis virus infection as a model for the development of antiviral therapies against HBV. Hollinger F.B., Lemon S.M., Margolis H. Viral Hepatitis and Liver Disease. 1991;663-665 Williams and Wilkins, Baltimore.
20. Korba, B.E., Cote, P.J., Hornbuckle, W.B., Tennant, B.C., Gerin, J.L., 2000. Treatment of chronic WHV infection in the Eastern woodchuck (M. monax) with nucleoside analogues as a model for therapy of chronic hepatitis B virus infection in man. Hepatology (in press).
21. Lai C.L., Ching C.K., Tung A.K., Li E., Young J., Hill A., Wong B.C., Dent J., Wu P.C. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology. 25:1997;241-244.
22. Lin E., Luscombe C., Colledge D., Wang Y.Y., Locarnini S. Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo. Antimicrob. Agents Chemother. 42:1998;2132-2137.
23. Mason W.S., Cullen J., Moraleda G., Saputelli J., Aldrich C.E., Miller D.S., Tennant B., Frick L., Averett D., Condreay L.D., Jilbert A.R. Lamivudine therapy of WHV-infected woodchucks. Virology. 245:1998;18-32.
24. Morrey J.D., Bailey K.W., Korba B.E., Sidwell R.W. Utilization of transgenic mice replicating high levels of hepatitis B virus for antiviral evaluation of lamivudine. Antiviral Res. 42:1999;97-108.
25. Ono N., Iwayama S., Suzuki K., Sekiyama T., Nakazawa H., Tsuji T., Okunishi M., Daikoku T., Nishiyama Y. Mode of action of (1′S,2′R)-9-[[1′,2′-bis(hydroxymethyl) cycloprop-1′-yl]methyl]guanine (A-5021) against herpes simplex virus type 1 and type 2 and varicella-zoster virus. Antimicrob. Agents Chemother. 42:1998;2095-2102.
26. Perigaud C., Gosselin G., Girardet J.-L., Korba B., Imbach J.-L. The SATE pronucleotide approach applied to acyclovir. Part I. Synthesis and in vitro anti-HBV activity of bis(SATE)phosphotriester derivatives of acyclovir. Antiviral Res. 40:1999;167-178.
27. Pillay D., Bartholomeusz A., Cane P., Mutimer D., Schinazi R., Locarnini S. Mutations in the hepatitis B virus DNA polymerase associated with antiviral resistance. Int. Antiviral News. 6:1998;167-169.
28. Ponzetto A., Cote P.J., Ford E.C., Purcell R.H., Gerin J.L. Core antigen and antibody in woodchucks after infection with woodchuck hepatitis virus. J. Virol. 52:1984;70-76.
29. Prichard M., Shipman C. Analysis of combinations of antiviral drugs and design of effective multidrug therapies. Antiviral Ther. 1:1996;9-20.
30. Summers J., Mason W.S. Replication of the genome of a hepatitis-B-like virus by reverse transcription of an RNA intermediate. Cell. 29:1982;403-415.
31. Tennant B.C., Hornbuckle W.E., Baldwin B.H., King J.M., Cote P., Popper H., Purcell R.H., Gerin J.L. Influence of age on the response to experimental woodchuck hepatitis virus infection. Zuckerman A.J. Viral Hepatitis and Liver Disease. 1988;462-464 A.R. Liss, New York.
32. Tennant B.C., Hornbuckle W.E., King J.M., Cote P.J., Popper H., Gerin J.L. HCC following experimental woodchuck hepatitis virus infection. Hollinger F.B., Lemon S.M., Margolis H. Viral Hepatitis and Liver Disease. 1991;678-681 Williams and Wilkins, Baltimore.
33. Tennant B.C., Baldwin B.H., Graham L.A., Ascenzi M.A., Hornbuckle W.E., Rowland P.H., Tochkov I.A., Yeager A.E., Erb H.N., Colacino J.M., Lopez C., Engelhardt J.A., Bowsher R.R., Richardson F.C., Lewis W., Cote P.J., Korba B.E., Gerin J.L. Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology. 28:1998;179-191.
34. Tennant B., Peek S., Tochkov I., Baldwin B., Hornbuckle W., Korba B., Cote P., Gerin J. The woodchuck in preclinical assessment of therapy for hepatitis B infection. Schinazi R., Sommadossi J., Thomas H. Therapies for Viral Hepatitis. 1998;171-176 International Medical Press, New York.
35. Tencza M.G., Newbold J.E. Heterogeneous response for a mammalian hepadnavirus infection to acyclovir: drug-arrested intermediates of minus-strand viral DNA synthesis are enveloped and secreted from infected cells as virion-like particles. J. Med. Virol. 51:1997;6-16.
36. Tsiquaye K.N., Sutton D., Maung M., Boyd M.R. Antiviral activities and pharmacokinetics of penciclovir and famciclovir in Pekin ducks chronically infected with duck hepatitis B virus. Antivir. Chem. Chemother. 7:1996;153-159.
37. Wong D.C., Shih J.W., Purcell R.H., Gerin J.L., London W.T. Natural and experimental infection of woodchucks with woodchuck hepatitis virus, as measured by new, specific assays for woodchuck surface antigen and antibody. J. Clin. Microbiol. 15:1982;484-490.
38. Zembower D., Lin Y.-H., Flavin M., Chen F.-C., Korba B. Robustaflavone, a potential non-nucleoside anti-hepatitis B agent. Antiviral Res. 39:1998;81-88.